Market Research Blog

Rapidly improving healthcare infrastructure and reimbursement scenario has been a major booster for the healthcare industry in developing regional markets. With incessantly increasing number of cancer cases, it is more likely that the subsequent demand for a wide range of treatments adopted to treat cancer patients would also remain on a constant rise over the course of coming years.

Radiation therapy has been a significant part of cancer treatment and the consistently high success rate associated with radiotherapy is projected to further push demand for radiation-induced myelosuppression treatment worldwide.

A new market research study on global radiation-induced myelosuppression treatment forecasts steady growth for the market in the next few years. Future Market Insights projects a moderate, just-under 4% yearly growth outlook, in 2022 and ahead.

Nutropenia is foreseen to generate maximum demand for radiation-induced myelosuppression treatment, whereas injectables are identified to hold a substantial share in the total market value, based on the route of administration of radiation-induced myelosuppression treatment. Thrombocytopenia and anemia are likely to present lucrative opporunities for radiation-induced myelosuppression treatment providers.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-8116

Report tracks key factors driving revenue growth of the market –

• Increasing prevalence of cancers
• Early diagnosis, promising improved chances of positive outcomes
• Fostering R&D funds supporting cancer research
• Strong product pipeline
• Bolstering adoption of chemo-radiotherapy in cancer treatment

In the backdrop of patent expiry, a majority of market leaders are shifting their focus to the expansion of product pipeline of a wide range of innovative formulations, likely to shape the radiation-induced myelosuppression treatment landscape.

• Myelo001 by Myelo Therapeutics GmbH recently received an FDA approval as an orphan drug to be used in the ARS (acute radiation syndrome) treatment.
• Mylan NV and Pfizer Inc. also reveived FDA approvals for their recently launched biosimilars – Epogen and Neupogen, and Neulasta respectively.

Patent expiry of originator biologics formulations is creating investment opportunities in biosimilars production – for the operators in radiation-induced myelosuppression treatment landscape. As there is a considerable cost difference of around 20% between originator biologics and biosimilars, patients are inclined more towards an economical means of treatment, thereby fueling the scope of penetration of radiation-induced myelosuppression treatment in coming years.

Request a Complete TOC of this Report with figures:
https://www.futuremarketinsights.com/toc/rep-gb-8116

Backed by a majority of established players housing strong bases across North America, especially the US, the report indicates a steady growth outlook for the radiation-induced myelosuppression treatment market in the region. North America will reportedly continue to account for over 65% share in the global market value.

New product launches currently mark the top developmental strategy adopted by leading companies competing in the radiation-induced myelosuppression treatment market. A majority of key players are also identified to focus on enhancing their geographical foothold in global radiation-induced myelosuppression treatment landscape.  The report in a distinct section covers some of the key competitors operating in radiation-induced myelosuppression treatment marketplace, emphasizing their financial as well as strategic profiles in depth.

A few of the profiled companies include Pfizer Inc., Janssen Pharmaceutical NV, Janssen Global Services, LLC (Johnson & Johnson), Amgen Inc., Mylan NV, Teva Pharmaceutical Industries Ltd., Novartis AG, and Partner Therapeutics, Inc.

In the highly consolidated competitive landscape of global radiation-induced myelosuppression treatment, the three top ranking companies, i.e. Janssen Pharmaceutical NV, Amgen Inc., and Teva Pharmaceutical Industries Ltd. dominate in terms of market value. These players continue to hold winning revenue shares in the radiation-induced myelosuppression treatment owing to strong global presence and a considerable number of new drug approvals. Established companies are entering strategic partnerships and collaborations with regional leaders, in an effort to achieve better penetration into regional markets.

For critical insights, request for PDF Brochure https://www.futuremarketinsights.com/reports/brochure/rep-gb-8116

About FMI:
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:
Mr. Debashish Roy
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

The global portable ultrasound bladder scanner market will reach a market value of ~US$ 110 Mn by 2022 end, which would see a healthy rise further, through 2029. As per the findings of a new Future Market Insights (FMI) report, the global portable ultrasound bladder scanner market will thrive on the back of rising adoption of non-invasive diagnostic procedures in urology imaging.

Advancements in ultrasound bladder scanner reduce the chance of catheter-associated urinary tract infection (CAUTI), reduce the time for operating procedures with no sonographer required, thus driving the growth of the portable ultrasound bladder scanner market during the forecast period. Distribution channels are well established for portable ultrasound bladder scanner due to increase in demand from end users such as hospitals, diagnostic centers, clinics and ambulatory surgical centers.

Key Takeaways – Portable Ultrasound Bladder Scanner Market Study

• The market share of 3D portable ultrasound bladder scanner devices is evaluated to grow at a significant rate by the end of 2029, as it provides high-end accuracy for measuring bladder volumes during urodynamics, thus surpassing the market of 2D portable ultrasound bladder scanner.
• Sales of portable ultrasound bladder scanner are envisaged to be higher in the region of North America. The rising prevalence of urological diseases among women and increasing adoption of portable ultrasound bladder scanner for diagnosis application are few factors contributing to the growth of the portable ultrasound bladder scanner market in the region.
• Portable US bladder scanners can be moved and carried to any location as and when required, due to its compact structure. One of the primary factors driving the portable bladder ultrasound scanner market is the accuracy and easy to use in both adults and children.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-2008

Portable Ultrasound Bladder Scanners Replacing Unnecessary Catheterization

Portable ultrasound bladder scanner has reduced the need for unnecessary catheterization, which also helps in the prevention of patients’ dignity and discomfort. Patients suffering from urological disorders opt for cardio portable ultrasound bladder scanner due to its less complex nature as compared to other diagnostic solutions. It also reduces the risk of catheter-associated urinary tract infection.

Such promising attributes facilitates the use of advanced portable ultrasound bladder scanners in hospitals, clinics, ambulatory surgical centers and others. Thus, enhanced patient care and addressing clinical challenges worldwide are expected to enhance demand for portable ultrasound bladder scanner during the forecast period.

Seeking More Information About Report Inclusions?

The portable ultrasound bladder scanner market, a new study from Future Market Insights, opines on the evolution of the portable ultrasound bladder scanner market from 2014 – 2021 and presents demand projections from 2022 – 2029 on the basis of product type (3D portable ultrasound bladder scanner, and 2D portable ultrasound bladder scanner), and end user (hospitals, diagnostic centers, clinics, and ambulatory surgical centers) in seven prominent regions.

For critical insights, request for PDF Brochure https://www.futuremarketinsights.com/reports/brochure/rep-gb-2008

About FMI:
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:
Mr. Debashish Roy
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

According to the latest research by Future Market Insights (FMI), global sales of home sleep screening devices exceeded the revenues worth US$ 3.1 billion in 2022. Toward 2023, FMI expects the revenue to observe robust increase by around 7%. According to the report, a majority of revenue through sales of home sleep devices will be generated by retail stores, the most preferred distribution channel for home sleep screening devices manufacturers, followed by the online sales segment.

In terms of revenue, the wearable sleep screening devices account for the revenue share of over 65% in the overall home sleep screening devices market. However, the increasing affordability and adoption of non-wearable devices for continuous sleep tracking without physical contact with the device is estimated to fuel the growth of the non-wearable home sleep screening devices segment in the near future.

Despite the fact that the rates of insurance reimbursement for home sleep studies are low, the convenience and portability offered by these devices compensate for the lack of reimbursement. A growing trend of using wearables as lifestyle devices is facilitating the demand for home sleep screening devices, and this is among the factors boosting the revenue generation of the home sleep screening devices market.

Prevalence of Sleep Related Disorders & Rising Number of Manufacturing Players Accelerating Market Reach of Home Sleep Screening Devices

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-8715

The growing demand for sleep studies with home sleep screening devices can be attributed to the growing prescription numbers for home sleep tracking. Sleep disorders are affecting a large pool of population, which has boosted the awareness about these disorders and other related ailments. Increase in the prevalence of sleep disorders has led to an expansion of private care centres and hospitals. These sleep centres have increased awareness among people about the importance of tracking sleep patterns for better sleep. This is driving the usage of home sleep screening devices for sleep disorder cases, and subsequently increasing the revenue generation of the home sleep screening devices market.

Increasing number of manufacturers in the home sleep screening devices landscape and growing awareness among patients about sleep-related disorders will fuel the demand for home sleep screening devices across the globe. There has been a consistent increase in the number of local manufacturers of sleep tracker systems, as well as the availability of different types of trackers such as wristbands, headbands, tracker masks, and ring devices. This enables customers to choose from a range of products depending on the data they want to analyze and the type of wearable preferred by them, based on which they can opt for a product based on their affordability as well as medical feasibility. This is majorly contributing to the growth of the home sleep screening devices market.

Advancing Sleep Tracking Technology to Uplift Sales Potential of Sleep Screening Devices

The technology utilised in home sleep screening devices is based on the mapping of the REM sleep, heal rate, respiration patterns, and deep sleep. However, new home sleep screening devices are incorporating the same technology as the one used in Actigraphy and polysomnography devices. The growing trend of utilising a sleep tracker as a lifestyle accessory is estimated to promote the growth of the home sleep screening devices market.

For any queries linked with the report, ask an analyst >> https://www.futuremarketinsights.com/ask-question/rep-gb-8715

Technological advancements in smart home sleep screening devices have led to the creation of hybrid devices that not only track activity, but also track sleeping patterns. These smart home sleep screening devices are capable of tracking fitness aspects such as the distance walked, calories consumed, heart rate monitoring, and can also track sleep patterns such as deep & light sleep and REM.

For instance, Fitbit, Inc.’s product Fitbit Ionic tracks fitness/activity as well as sleep patterns. It can record the REM, deep & light sleep, as well as provide tips for efficient sleeping patterns based on an individual’s lifestyle. Similar technological trends are estimated to eliminate the factors restraining the growth of the home sleep screening devices market.

The Consumer Electronics Association has collaborated with The National Sleep Foundation and formed “The Wearable Sleep Monitoring Equipment Group,” which is aimed at boosting the development of sleep technologies. This is also expected to improve the quality of wearable home sleep screening devices to ensure better data collection and storage. The introduction of certain new advancements and technologies are expected to create growth opportunities for the home sleep screening device market.

The report tracks some of the key companies operating in the home sleep screening devices market, which include Fitbit, Inc., Koninklijke Philips N.V., Huami Corporation, Fossil Group, Inc., Garmin Ltd., Huawei Technologies Co., Ltd., ResMed Inc., Responsive Surface Technology, LLC, and Simmons Bedding Company LLC.

Request a Complete TOC of this Report with figures:
https://www.futuremarketinsights.com/toc/rep-gb-8715

About FMI:
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:
Mr. Debashish Roy
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

A new market research report by Future Market Insights on the atopic dermatitis treatment market includes global industry analysis 2014–2021 and opportunity assessment 2022–2029. The report investigates the atopic dermatitis treatment market and provides critical insights for the forecast period of 2022-2029. As per the findings of the report, the global atopic dermatitis treatment market is projected to experience significant growth over the forecast period, due to increasing prevalence, promising pipeline molecules, higher treatment compliance, increasing access to treatment medication in developing countries, favorable reimbursement policies, increasing government support for research and development, and advancing technology.

The global atopic dermatitis treatment market was valued ~ US$ 5.2 Bn in 2021, and is expected to increase at a CAGR of ~4.8% during the forecast period of 2022 and 2029.

Corticosteroids Remain the Drug of Choice

Corticosteroids are referred as the first choice of treatment for the inflammation and pain relief. These medications are known to have effects, for example, decreasing tingling, allergic reaction, swelling and redness.

Around 30 corticosteroid compounds have been licensed for atopic dermatitis treatment, of which ‘hydrocortisone’ is considered as the first. In addition, increasing innovations have resulted in the advent of topical non-corticosteroids immunomodulators and target medications, for example, immunomodulators such as pimecrolimus and tacrolimus, which in turn, is likely to fuel the growth of the atopic dermatitis treatment market. Moreover, topical corticosteroids are expected to play an important roles in the atopic dermatitis treatment.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-3097

North America to Offer High Sales Opportunities

Growth prospects of the atopic dermatitis treatment market are likely to be high in North America over the forecast period of 2022-2029. Factors such as, greater treatment awareness among the patient population across the United States and Canada, early adoption of novel prescriptions, advanced healthcare infrastructure, better and favorable reimbursement policies, and increasing business associations of pharmaceutical organizations with contract research organizations in developing markets will continue to  propel the atopic dermatitis treatment market growth. Despite the fact that the U.S and Canada deal with heavy investment in healthcare infrastructure as well as per capita expenditure, there are increasing number of campaigns organized each year by specific establishments, for example, National Eczema Associations, the PAN Foundation, and pharmaceutical organizations, which are envisaged to work to the advantage of several market vendors.

Hospital Pharmacies – The Key Distribution Channel for Atopic Dermatitis Treatment

Sales of medication for atopic dermatitis treatment through hospital pharmacies will continue to account for relatively high share in the market, as they can stock large range of prescription medicines, including progressively specific and investigational medications. Hospital pharmacies may provide a tremendous amount of medications every day, which is distributed to wards and to intensive care units as per the patient’s prescription schedule.

Topical Drug Administration- A Preferred Mode

Topical mode of administration remains highly preferred among the patient pool of atopic dermatitis. Advent of topical non-corticosteroids immunomodulators is the major factor for the growth in the demand for atopic dermatitis treatment. As topical administration gains prominence, major corticosteroids medications are formulated as topical, in addition to their benefits over oral dosage form.

Atopic Dermatitis Treatment Market: Vendor Insights

The report highlights some of the prominent market players, who have established themselves as leaders in the global atopic dermatitis treatment market. Some of the examples of key players in the global atopic dermatitis treatment market are Sanofi S.A., Galderma S.A., Allergan Plc., Novartis, Bristol-Myers Squibb, Bayer AG, Meda Pharmaceuticals Inc., Astellas Pharma, Inc., Anacor Pharmaceuticals, Inc., Regeneron Pharmaceuticals, and Valeant Pharmaceuticals International, Inc.

For critical insights, request for PDF Brochure https://www.futuremarketinsights.com/reports/brochure/rep-gb-3097

About FMI:
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:
Mr. Debashish Roy
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com